NASDAQ:DWTX Dogwood Therapeutics Q2 2025 Earnings Results & Report $1.40 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.47 +0.07 (+5.00%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Dogwood Therapeutics missed analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$1.99 versus the -$1.26 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 13, 2025TimeBefore Market OpensConference Call9:30 AM ET Dogwood Therapeutics EPS ResultsActual EPS-$1.99Consensus EPS -$1.26Beat/MissMissed by -$0.73One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersDogwood Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsDogwood Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dogwood Therapeutics Q2 2025 Earnings FAQ Did Dogwood Therapeutics beat earnings estimates for Q2 2025? Dogwood Therapeutics (NASDAQ:DWTX) reported earnings of -$1.99 per share for Q2 2025, missing the consensus estimate of -$1.26. The report was announced on Wednesday, August 13, 2025. When is Dogwood Therapeutics' next earnings date? Dogwood Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dogwood Therapeutics on the company's earnings history page. Dogwood Therapeutics Earnings HeadlinesDogwood Therapeutics (NASDAQ:DWTX) Stock Price Down 5.9% - Time to Sell?October 8, 2026 | americanbankingnews.comDogwood to Participate in the 2026 Maxim Growth SummitOctober 6, 2026 | globenewswire.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 12 at 1:00 AM | Weiss Ratings (Ad)Dogwood Therapeutics Stock Price HistorySeptember 15, 2026 | investing.comDogwood Completes Enrollment In Halneuron Phase 2b CINP Trial; Topline Data Due NovemberSeptember 14, 2026 | rttnews.comDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialSeptember 14, 2026 | globenewswire.comSee More Dogwood Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email. Email Address About Dogwood TherapeuticsDogwood Therapeutics (NASDAQ:DWTX). is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression. Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID. The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development. Its programs remain investigational and are subject to clinical testing and regulatory review. Publicly available information about its geographic operations and leadership is limited.View Dogwood Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
